See more : Li-Cycle Holdings Corp. (LICY) Income Statement Analysis – Financial Results
Complete financial analysis of Evercore Inc. (EVR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Evercore Inc., a leading company in the Financial – Capital Markets industry within the Financial Services sector.
You may be interested
- YANGAROO Inc. (YOO.V) Income Statement Analysis – Financial Results
- Shri Krishna Devcon Limited (SHRIKRISH.BO) Income Statement Analysis – Financial Results
- EL.En. S.p.A. (ELN.MI) Income Statement Analysis – Financial Results
- Fancamp Exploration Ltd. (FNCJF) Income Statement Analysis – Financial Results
- The Bancorp, Inc. (TBBK) Income Statement Analysis – Financial Results
Evercore Inc. (EVR)
About Evercore Inc.
Evercore Inc., together with its subsidiaries, operates as an independent investment banking advisory firm in the United States, Europe, Latin America, and internationally. It operates through two segments, Investment Banking and Investment Management. The Investment Banking segment offers strategic advisory services, such as mergers and acquisitions, strategic, defense, and shareholder advisory, special committee assignments, and transaction structuring; Capital Markets Advisory, including equity capital markets, restructuring, debt advisory, private placement advisory, market risk management and hedging, private capital advisory, and private funds; and research, sales, and trading professionals services on a content-led platform to its institutional investor clients. The Investment Management segment provides wealth management services to high-net-worth individuals, foundations, and endowments; and manages financial assets for institutional investors. The company was formerly known as Evercore Partners Inc. and changed its name to Evercore Inc. in August 2017. Evercore Inc. was founded in 1995 and is headquartered in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.43B | 2.76B | 3.29B | 2.26B | 2.01B | 2.06B | 1.70B | 1.44B | 1.22B | 915.86M | 765.43M | 642.37M | 524.26M | 378.90M | 313.14M | 194.66M | 321.60M | 208.00M | 125.64M | 86.32M | 60.12M |
| Cost of Revenue | 62.06M | 1.80B | 1.96B | 1.49B | 1.31B | 1.29B | 1.05B | 990.47M | 878.07M | 613.67M | 538.73M | 483.08M | 398.36M | 280.05M | 233.44M | 164.83M | 319.90M | 29.06M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 2.36B | 958.34M | 1.33B | 774.52M | 697.42M | 778.10M | 651.38M | 449.58M | 345.21M | 302.19M | 226.70M | 159.30M | 125.91M | 98.85M | 79.70M | 29.83M | 1.70M | 178.94M | 125.64M | 86.32M | 60.12M |
| Gross Profit Ratio | 97.44% | 34.70% | 40.32% | 34.21% | 34.72% | 37.69% | 38.22% | 31.22% | 28.22% | 33.00% | 29.62% | 24.80% | 24.02% | 26.09% | 25.45% | 15.32% | 0.53% | 86.03% | 100.00% | 100.00% | 100.00% |
| Research & Development | 0.00 | 0.25 | 0.34 | 0.24 | 0.22 | 0.26 | 0.25 | 0.18 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 1.66B | 1.70B | 1.85B | 1.37B | 1.20B | 1.20B | 962.51M | 900.59M | 788.18M | 549.52M | 485.79M | 430.42M | 357.68M | 251.92M | 210.82M | 146.66M | 299.33M | 72.91M | 24.12M | 17.08M | 12.45M |
| Selling & Marketing | 193.13M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.85B | 1.70B | 1.85B | 1.37B | 1.20B | 1.20B | 962.51M | 900.59M | 788.18M | 549.52M | 485.79M | 430.42M | 357.68M | 251.92M | 210.82M | 146.66M | 299.33M | 72.91M | 24.12M | 17.08M | 12.45M |
| Other Expenses | 0.00 | -1.98B | -4.15B | -3.16B | -2.82B | -2.86B | -1.23B | -1.15B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -83.23M | 76.00K | -37.32M |
| Operating Expenses | 1.85B | 172.77M | -2.30B | -1.79B | -1.62B | -1.55B | 65.06M | 57.67M | 50.82M | 45.43M | 36.45M | 35.51M | 33.52M | 28.46M | 20.93M | 16.17M | 28.69M | 23.89M | -59.11M | 21.32M | -24.87M |
| Cost & Expenses | 1.85B | 1.98B | -2.30B | -1.79B | -1.62B | -1.55B | 1.12B | 1.05B | 928.88M | 659.09M | 575.18M | 518.58M | 431.87M | 308.51M | 254.37M | 181.00M | 348.59M | 52.95M | -59.11M | 21.32M | -24.87M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 24.14M | 9.27M | 209.00K | 145.00K | 250.00K |
| Interest Expense | 16.72M | 16.85M | 17.59M | 21.41M | 20.14M | 17.77M | 20.00M | 16.74M | 16.98M | 15.54M | 14.01M | 15.30M | 19.39M | 22.84M | 24.27M | 30.28M | 18.45M | 8.50M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 66.50M | 2.06B | 2.18B | 1.69B | 1.56B | 1.52B | 1.25B | 1.17B | 27.93M | 16.26M | 14.54M | 16.83M | 17.75M | 10.08M | 4.52M | 4.62M | 17.42M | 4.51M | 778.00K | 667.00K | 626.00K |
| EBITDA | 445.27M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 219.61M | 213.48M | 158.95M | 101.12M | 74.11M | 44.93M | 45.14M | 0.00 | 0.00 | 100.36M | 0.00 | 0.00 | 0.00 |
| EBITDA Ratio | 18.35% | 25.15% | 30.89% | 22.31% | 21.08% | 25.81% | 25.23% | 18.67% | 13.61% | 20.74% | 19.29% | 14.61% | 13.25% | 15.63% | 15.36% | 15.60% | 4.28% | 43.82% | 53.57% | 60.89% | 59.67% |
| Operating Income | 575.94M | 666.93M | 988.14M | 478.73M | 392.48M | 503.53M | 403.89M | 243.57M | 136.87M | 171.17M | 130.96M | 75.10M | 49.07M | 47.68M | 42.23M | 25.74M | -3.64M | 86.64M | 66.52M | 51.89M | 35.25M |
| Operating Income Ratio | 23.74% | 24.15% | 30.04% | 21.15% | 19.54% | 24.39% | 23.70% | 16.91% | 11.19% | 18.69% | 17.11% | 11.69% | 9.36% | 12.58% | 13.49% | 13.23% | -1.13% | 41.65% | 52.95% | 60.12% | 58.63% |
| Total Other Income/Expenses | -210.15M | -173.76M | -149.59M | -226.55M | -208.88M | -174.80M | -117.81M | -169.94M | -203.40M | -111.52M | -85.90M | -24.81M | -19.63M | 1.45M | -20.84M | -35.13M | -46.40M | -6.22M | 66.53M | 29.00K | -9.00K |
| Income Before Tax | 365.79M | 704.04M | 1.12B | 540.83M | 448.71M | 551.37M | 437.65M | 267.82M | 134.72M | 176.13M | 138.50M | 70.39M | 36.73M | 33.69M | 19.78M | -9.38M | -54.94M | 94.13M | 66.53M | 51.92M | 35.24M |
| Income Before Tax Ratio | 15.08% | 25.49% | 33.94% | 23.89% | 22.34% | 26.70% | 25.68% | 18.60% | 11.01% | 19.23% | 18.09% | 10.96% | 7.01% | 8.89% | 6.32% | -4.82% | -17.08% | 45.26% | 52.96% | 60.15% | 58.62% |
| Income Tax Expense | 80.57M | 172.63M | 248.03M | 128.15M | 95.05M | 108.52M | 258.44M | 119.30M | 77.03M | 68.76M | 63.69M | 30.91M | 22.72M | 15.88M | 19.53M | 179.00K | 12.40M | 8.40M | 3.37M | 2.11M | 905.00K |
| Net Income | 255.48M | 476.52M | 740.12M | 350.57M | 297.44M | 377.24M | 125.45M | 107.53M | 42.86M | 86.87M | 53.26M | 28.89M | 6.95M | 8.95M | -1.57M | -4.71M | -34.50M | 69.74M | 63.15M | 49.78M | 34.34M |
| Net Income Ratio | 10.53% | 17.25% | 22.50% | 15.49% | 14.81% | 18.27% | 7.36% | 7.47% | 3.50% | 9.49% | 6.96% | 4.50% | 1.33% | 2.36% | -0.50% | -2.42% | -10.73% | 33.53% | 50.27% | 57.67% | 57.13% |
| EPS | 6.71 | 12.15 | 18.48 | 8.64 | 7.44 | 8.33 | 3.16 | 2.74 | 1.15 | 2.42 | 1.65 | 0.98 | 0.26 | 0.45 | -0.10 | -0.36 | -3.38 | 10.97 | 15.81 | 12.46 | 8.60 |
| EPS Diluted | 6.37 | 11.61 | 17.08 | 8.23 | 6.89 | 8.33 | 2.80 | 2.43 | 0.98 | 2.08 | 1.38 | 0.89 | 0.23 | 0.39 | -0.10 | -0.36 | -3.38 | 10.97 | 15.81 | 12.46 | 8.60 |
| Weighted Avg Shares Out | 38.10M | 39.22M | 40.05M | 40.55M | 39.99M | 45.28M | 39.64M | 39.22M | 37.16M | 35.83M | 32.21M | 29.28M | 26.02M | 19.66M | 15.55M | 13.07M | 10.22M | 6.36M | 4.00M | 4.00M | 4.00M |
| Weighted Avg Shares Out (Dil) | 40.10M | 41.04M | 43.32M | 42.62M | 43.19M | 45.28M | 44.83M | 44.19M | 43.70M | 41.84M | 38.48M | 32.55M | 29.40M | 22.97M | 15.55M | 13.07M | 10.22M | 6.36M | 4.00M | 4.00M | 4.00M |
Contineum Therapeutics to Attend the 7th Annual Evercore HealthCONx Conference
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments in the treatment of neuroscience,...
Why Is Evercore (EVR) Up 17.8% Since Last Earnings Report?
Evercore (EVR) reported earnings 30 days ago. What's next for the stock?
Protagonist Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference 2024
NEWARK, CA / ACCESSWIRE / November 22, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D.
Merck to Participate in the 7th Annual Evercore ISI HealthCONx Conference
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the 7th Annual Evercore ISI HealthCONx Conference.
Evercore's Emanuel Sees S&P 500 at 6,600 by Mid-2025
Julian Emanuel, chief equity and quantitative strategist at Evercore ISI, sees markets in a “digestion phase” following the election of Donald Trump as US president and says, “the bond market is going to call the tune” for at least the...
Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference
WATERTOWN, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer...
BD to Present at the 7th Annual Evercore ISI HealthCONx Conference
FRANKLIN LAKES, N.J. , Nov. 19, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday, December 3,...
Baxter to Present at 7th Annual Evercore HealthCONx Conference
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the 7th Annual Evercore HealthCONx Conference on Thursday, December 5, 2024. Joel Grade, Baxter's chief financial officer, is scheduled to present at 9:10 a.m. Eastern Time. The...
Cidara Therapeutics to Participate in Evercore 7th Annual HealthCONx Conference
SAN DIEGO, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing...
Evercore ISI's Mark Mahaney on how self-driving deregulation could impact Uber and Lyft
Mark Mahaney, Evercore ISI Head of Internet Research, joins 'Fast Money' to talk possible deregulation of self-driving under a Trump administration.
Source: https://incomestatements.info
Category: Stock Reports